Cas:912762-56-2 [2-(4-fluoro-phenyl)-2-hydroxyimino-ethyl]-carbamic acid tert-butyl ester manufacturer & supplier

Chemical Name:[2-(4-fluoro-phenyl)-2-hydroxyimino-ethyl]-carbamic acid tert-butyl ester

CAS.NO:912762-56-2

Synonyms:[2-(4-fluoro-phenyl)-2-hydroxyimino-ethyl]-carbamic acid tert-butyl ester

Molecular Formula:C₁₃H₁₇FN₂O₃

Molecular Weight:268.28400

HS Code:2928000090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:401.2ºC at 760 mmHg

Density:1.16g/cm3

Index of Refraction:1.512

PSA:70.92000

Exact Mass:268.12200

LogP:2.91960

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like [2-(4-fluoro-phenyl)-2-hydroxyimino-ethyl]-carbamic acid tert-butyl ester chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,[2-(4-fluoro-phenyl)-2-hydroxyimino-ethyl]-carbamic acid tert-butyl ester physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,[2-(4-fluoro-phenyl)-2-hydroxyimino-ethyl]-carbamic acid tert-butyl ester Use and application,[2-(4-fluoro-phenyl)-2-hydroxyimino-ethyl]-carbamic acid tert-butyl ester technical grade,usp/ep/jp grade.

Related News: The acquired pharmaceutical intermediates business will be renamed Corden Pharma Switzerland LLC and will operate as part of ICIG��s pharmaceutical business within the Corden Pharma platform. The companies�� goal is to close the transaction during the first quarter of 2011. Financial terms are not disclosed. [2-(4-fluoro-phenyl)-2-hydroxyimino-ethyl]-carbamic acid tert-butyl ester manufacturer As proof-of-principle for the unique advantages arising from selecting a single engineered iPSC clone for the production of CAR T-cell therapy, the scientists assessed 747 clones after engineering a pool of cells using CRISPR. It was found that only about 2% of clones met the Company��s standards for overall quality including containing both bi-allelic disruption of the TCR, proper insertion of the CAR into the TRAC locus without random transgene integrations, and no evidence of off-target genomic modifications or translocations. [2-(4-fluoro-phenyl)-2-hydroxyimino-ethyl]-carbamic acid tert-butyl ester supplier ��Administrative Measures for the Joint Review, Review and Approval of Raw Materials, Medicinal Auxiliaries and Pharmaceutical Packaging Materials and Pharmaceutical Preparations�� (Consultation Draft) issued by the State Food and Drug Administration in December 2017. Supervision departments no longer accept applications for registration of APIs, pharmaceutical excipients, and packaging materials. [2-(4-fluoro-phenyl)-2-hydroxyimino-ethyl]-carbamic acid tert-butyl ester vendor Government prosecutors often consider whether a corporation made a genuine effort to investigate and address potentially illegal activities once learning of them. [2-(4-fluoro-phenyl)-2-hydroxyimino-ethyl]-carbamic acid tert-butyl ester factory As proof-of-principle for the unique advantages arising from selecting a single engineered iPSC clone for the production of CAR T-cell therapy, the scientists assessed 747 clones after engineering a pool of cells using CRISPR. It was found that only about 2% of clones met the Company��s standards for overall quality including containing both bi-allelic disruption of the TCR, proper insertion of the CAR into the TRAC locus without random transgene integrations, and no evidence of off-target genomic modifications or translocations.